Literature DB >> 18802898

Site-specific rectocele repair with dermal graft augmentation: comparison of porcine dermal xenograft (Pelvicol) and human dermal allograft.

Roger C Biehl1, Robert D Moore, John R Miklos, Neeraj Kohli, Indu S Anand, T Fleming Mattox.   

Abstract

This study is a retrospective chart review comparing 195 women who underwent rectocele repair with either a porcine dermal xenograft or human allogenic cadaveric dermal graft augmentation over a two year period. A site-specific defect repair was completed prior to augmentation with the graft. Examinations were performed preoperatively and postoperatively using the pelvic organ prolapse quantification system. Questionnaires were used to assess constipation and dyspareunia. De novo dyspareunia and cure rates for constipation and dyspareunia were not statistically different between the two groups. Site-specific fascial rectocele repairs with xenograft or allograft augmentation were found to have similar complication rates as well as objective and subjective cure rates.

Entities:  

Mesh:

Year:  2008        PMID: 18802898

Source DB:  PubMed          Journal:  Surg Technol Int        ISSN: 1090-3941


  3 in total

1.  Long-term outcomes after native tissue vs. biological graft-augmented repair in the posterior compartment.

Authors:  Cara L Grimes; Jasmine Tan-Kim; Emily L Whitcomb; Emily S Lukacz; Shawn A Menefee
Journal:  Int Urogynecol J       Date:  2011-11-24       Impact factor: 2.894

2.  Surgical interventions for posterior compartment prolapse and obstructed defecation symptoms: a systematic review with clinical practice recommendations.

Authors:  Cara L Grimes; Megan O Schimpf; Cecilia K Wieslander; Ambereen Sleemi; Paula Doyle; You Maria Wu; Ruchira Singh; Ethan M Balk; David D Rahn
Journal:  Int Urogynecol J       Date:  2019-06-29       Impact factor: 2.894

3.  Transvaginal rectocele repair with human dermal allograft interposition and bilateral sacrospinous fixation with a minimum eight-year follow-up.

Authors:  Serge P Marinkovic; Scott Hughes; Donghua Xie; Lisa M Gillen; Christina M Marinkovic
Journal:  BMC Urol       Date:  2016-03-25       Impact factor: 2.264

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.